PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway

Leukemia

Volumn 28, Issue 7, 2014, Pages 1436-1448

  Zhou, J ^a   Wu, J ^b   Li, B ^a,b,c   Liu, D ^a,b   Yu, J ^d   Yan, X ^c   Zheng, S ^a,b   Wang, J ^a,e   Zhang, L ^a,b   He, F ^a   Li, Q ^a   Chen, A ^a,b,c   Zhang, Y ^c   Zhao, X ^a,c   Guan, Y ^f   Yan, J ^a   Ni, J ^g   Nobrega, M A ^h   Lowenberg B ⁱ   Delwel, R ⁱ   Valk, P J M ⁱ   Kumar, A ^c   Xie, L ^d   Tenen, D G ^j,k   Huang, G ^c   Wang, Q F ^a   more..

^a Chinese Academy of Sciences   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d SHANGHAI CENTER FOR BIOINFORMATION TECHNOLOGY   (China)

^e Department of Biomedical Informatics and Center for Computational Biology Bioinformatics Columbia University ^*  (United States)

^f THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^g HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^k HARVARD STEM CELL INSTITUTE   (United States)

more..

Author keywords

MEIS1; MLL leukemia; PU.1; transcription regulation

Indexed keywords

FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HOX PROTEIN; INTERLEUKIN 3; INTERLEUKIN 6; MEIS1 PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR PU 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MIXED LINEAGE LEUKEMIA; MOLECULAR INTERACTION; MOUSE; MYELOBLAST; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION INITIATION SITE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, BIPHENOTYPIC, ACUTE; MICE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; TRANS-ACTIVATORS;

EID: 84904040001     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.384     Document Type: Article

References (56)

1. Krivtsov A, Armstrong S. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007 7 823.
2. de Boer J, Walf-Vorderwu? lbecke V, Williams O. In focus MLL rearranged leukemia. Leukemia 2013 27 1224-1228.
3. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009 23 1490-1499.
4. Nakamura T, Alder H, Gu Y, Prasad R, Canaani O, Kamada N et al. Genes on chromosomes 4, 9 and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs. Natl Acad Sci USA 1993 90 4631-4635.
5. Bitoun E, Oliver P, Davies K. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 2007 16 92.
6. Mueller D, Bach C, Zeisig D, Garcia-Cuellar M, Monroe S, Sreekumar A et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 2007 110 4445.
7. Greaves M, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003 3 639.
8. Balgobind B, Zwaan C, Pieters R, Van den Heuvel-Eibrink M. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia 2011 25 1239-1248.
9. Rosenbauer F, Tenen DG. Transcription factors in myeloid development balancing differentiation with transformation. Nat Rev Immunol 2007 7 105-117.
10. Armstrong S, Staunton J, Silverman L, Pieters R, den Boer M, Minden M et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002 30 41.
11. Valk PJM, Verhaak RGW, Beijen MA, Erpelinck CAJ, van Doorn-Khosrovani SBW, Boer JM et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004 350 1617-1628.
12. Ross ME, Mahfouz R, Onciu M, Liu HC, Zhou X, Song G et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004 104 3679-3687.
13. Zeisig BB, Milne T, Garca-Cue? llar MP, Schreiner S, Martin ME, Fuchs U et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 2004 24 617-628.
14. Martin ME, Milne TA, Bloyer S, Galoian K, Shen W, Gibbs D et al. Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer cell 2003 4 197-207.
15. So CW, Lin M, Ayton PM, Chen EH, Cleary ML. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer cell 2003 4 99-110.
16. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003 17 2298.
17. Wang J, Iwasaki H, Krivtsov A, Febbo PG, Thorner AR, Ernst P et al. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J 2005 24 368.
18. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield V et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005 121 167.
19. Kumar A, Hudson W, Chen W, Nishiuchi R, Yao Q, Kersey J. Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia. Blood 2004 103 1823.
20. Kumar AR, Li Q, Hudson WA, Chen W, Sam T, Yao Q et al. A role for MEIS1 in MLLfusion gene leukemia. Blood 2009 113 1756.
21. Wong P, Iwasaki M, Somervaille TC, So CWE, Cleary ML. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev 2007 21 2762.
22. Mann RS, Lelli KM, Joshi R. Hox specificity unique roles for cofactors and collaborators. Curr Top Dev Biol 2009 88 63-101.
23. Huang Y, Sitwala K, Bronstein J, Sanders D, Dandekar M, Collins C et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood 2012 119 388-398.
24. Hu Y-L, Fong S, Ferrell C, Largman C, Shen W-F. HOXA9 modulates its oncogenic partner Meis1 to influence normal hematopoiesis. Mol Cell Biol 2009 29 5181-5192.
25. Wang GG, Pasillas MP, Kamps MP. Persistent transactivation by Meis1 replaces Hox function in myeloid leukemogenesis models evidence for co-occupancy of Meis1-Pbx and Hox-Pbx complexes on promoters of leukemia-associated genes. Mol Cell Biol 2006 26 3902.
26. Wang GG, Pasillas MP, Kamps MP. Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus. Blood 2005 106 254-264.
27. Wang Q-f, Li Y-j, Dong J-f, Li B, Kaberlein JJ, Zhang L et al. Regulation of MEIS1 by distal enhancer elements in acute leukemia. Leukemia 2013 28 138-146.
28. Huang G, Zhang P, Hirai H, Elf S, Yan X, Chen Z et al. PU. 1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nature Genet 2008 40 51.
29. Iwasaki H, Somoza C, Shigematsu H, Duprez EA, Iwasaki-Arai J, Mizuno S et al. Distinctive and indispensable roles of PU. 1 in maintenance of hematopoietic stem cells and their differentiation. Blood 2005 106 1590-1600.
30. Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, Okuno Y et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU. 1. Nature Genet 2004 36 624-630.
31. Zhang Y, Yan X, Sashida G, Zhao X, Rao Y, Goyama S et al. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. Blood 2012 120 1118-1129.
32. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 2009 94 131.
33. Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, Miner T et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 2008 111 4797.
34. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Te Kronnie G, Be?ne? M-C et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010 28 2529-2537.
35. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 2008 112 4193-4201.
36. Wilson NK, Foster SD, Wang X, Knezevic K, Schu? tte J, Kaimakis P et al. Combinatorial transcriptional control in blood stem/progenitor cells genomewide analysis of ten major transcriptional regulators. Cell Stem Cell 2010 7 532-544.
37. Lefterova MI, Steger DJ, Zhuo D, Qatanani M, Mullican SE, Tuteja G et al. Cell-Specific Determinants of Peroxisome Proliferator-Activated Receptor g Function in Adipocytes and Macrophages. Mol Cell Biol 2010 30 2078.
38. Barash Y, Dehan E, Krupsky M, Franklin W, Geraci M, Friedman N et al. Comparative analysis of algorithms for signal quantitation from oligonucleotide microarrays. Bioinformatics 2004 20 839.
39. Wang Q-f, Wu G, Mi S, He F, Wu J, Dong J et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood 2011 117 6895-6905.
40. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV et al. MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L. Cancer cell 2011 20 66-78.
41. Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev 2011 25 1628-1640.
42. Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL et al. Aberrant chromatin at genes encoding stem cell regulators in human mixedlineage leukemia. Genes Dev 2008 22 3403-3408.
43. Knezevic K, Bee T, Wilson NK, Janes ME, Kinston S, Polderdijk S et al. A Runx1-Smad6 Rheostat Controls Runx1 Activity during Embryonic Hematopoiesis. Mol Cell Biol 2011 31 2817.
44. Poirel H, Rack K, Delabesse E, Radford-Weiss I, Troussard X, Debert C et al. Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5. Blood 1996 87 2496-2505.
45. Rabbitts T. Chromosomal translocations in human cancer. Nature 1994 372 143.
46. Swansbury G. The proportion of clonal divisions varies in different hematologic malignancies. The United Kingdom Cancer Cytogenetics Group (UKCCG) [corrected]. Cancer Genet Cytogenet 1998 104 139.
47. Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG et al. The myeloid master regulator transcription factor PU. 1 is inactivated by AML1-ETO in t (8 21) myeloid leukemia. Blood 2003 101 270-277.
48. Wang K, Wang P, Shi J, Zhu X, He M, Jia X et al. PML/RARalpha targets promoter regions containing PU. 1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer cell 2010 17 186.
49. Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N et al. ATRA resolves the differentiation block in t (15 17) acute myeloid leukemia by restoring PU. 1 expression. Blood 2006 107 3330.
50. Harrell F, Lee KL, Mark DB. Tutorial in biostatistics multivariable prognostic models issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996 15 361-387.
51. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 7 177-188.
52. Venet D, Dumont JE, Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 2011 7 e1002240.
53. Cook WD, McCaw BJ, Herring C, John DL, Foote SJ, Nutt SL et al. PU. 1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain. Blood 2004 104 3437-3444.
54. Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD et al. Heterozygous PU. 1 mutations are associated with acute myeloid leukemia. Blood 2002 100 998-1007.
55. Aikawa Y, Katsumoto T, Zhang P, Shima H, Shino M, Terui K et al. PU. 1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2. Nature Med 2010 16 580-585.
56. Staber P, Zhang P, Ye M, Welner R, Nombela-Arrieta C, Bach C et al Sustained PU 1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells Mol Cell 2013 49 934-946